Jacobs Levy Equity Management
FULC icon

Jacobs Levy Equity Management’s Fulcrum Therapeutics FULC Stock Holding History

Jacobs Levy Equity Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70,015
Closed -$644K – 974
2025
Q3 		$644K Sell
70,015
-22,455
-24% -$162K ﹤0.01% 784
2025
Q2 		$636K Sell
92,470
-55,184
-37% -$295K ﹤0.01% 834
2025
Q1 		$425K Buy
+147,654
New +$542K ﹤0.01% 938
2024
Q4 		– Sell
-202,030
Closed -$721K – 981
2024
Q3 		$721K Buy
+202,030
New +$1.5M ﹤0.01% 783
2024
Q2 		– Sell
-20,472
Closed -$193K – 996
2024
Q1 		$193K Sell
20,472
-101,658
-83% -$907K ﹤0.01% 894
2023
Q4 		$824K Sell
122,130
-143,376
-54% -$636K ﹤0.01% 755
2023
Q3 		$1.18M Buy
+265,506
New +$1.16M 0.01% 646
2021
Q4 		– Sell
-7,487
Closed -$211K – 1009
2021
Q3 		$211K Sell
7,487
-6,302
-46% -$119K ﹤0.01% 981
2021
Q2 		$145K Buy
+13,789
New +$139K ﹤0.01% 1004
2021
Q1 		– Sell
-15,692
Closed -$184K – 1056
2020
Q4 		$184K Sell
15,692
-647
-4% -$7.32K ﹤0.01% 967
2020
Q3 		$130K Sell
16,339
-2,355
-13% -$28.4K ﹤0.01% 988
2020
Q2 		$342K Buy
18,694
+7,502
+67% +$118K ﹤0.01% 861
2020
Q1 		$134K Buy
+11,192
New +$179K ﹤0.01% 936

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management's FULC Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 70,015 shares — an estimated $644K sold.

Jacobs Levy Equity Management first reported a position in FULC in Q1 2020 and held it in 13 quarters. The position peaked at $1.18M in Q3 2023. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 70,015 Fulcrum Therapeutics shares in Q4 2025, an estimated $644K.
  • Jacobs Levy Equity Management first reported a position in Fulcrum Therapeutics in Q1 2020 and held it in 13 quarters.
  • Jacobs Levy Equity Management's Fulcrum Therapeutics position peaked at $1.18M in Q3 2023.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.